- £230.97m
- £225.46m
- £12.82m
- 97
- 18
- 47
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.3 | ||
| PEG Ratio (f) | 3.35 | ||
| EPS Growth (f) | 7.83% | ||
| Dividend Yield (f) | 3.95% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.86 | ||
| Price to Tang. Book | 19.86 | ||
| Price to Free Cashflow | 28.41 | ||
| Price to Sales | 16.7 | ||
| EV to EBITDA | 20.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 93.51% | ||
| Return on Equity | 79.14% | ||
| Operating Margin | 78.69% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 9.29 | 10.31 | 10.93 | 11.72 | 12.82 | 14 | 15.1 | 7.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +3.51 | +23.02 | -7.24 | +14.04 | +8.48 | +5 | +7.88 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 7th, 2003
- Public Since
- April 29th, 2014
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 5,219,656
- Address
- 7 Romans Business Park, East Street, FARNHAM, GU9 7SX
- Web
- https://www.bioventix.com/
- Phone
- +44 1252728001
- Auditors
- Kreston Reeves LLP
Latest News for BVXP
Upcoming Events for BVXP
Full Year 2024 Bioventix PLC Earnings Release
Bioventix PLC Annual Shareholders Meeting
Similar to BVXP
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:37 UTC, shares in Bioventix are trading at 4,350.00p. This share price information is delayed by 15 minutes.
Shares in Bioventix last closed at 4,350.00p and the price had moved by +11.54% over the past 365 days. In terms of relative price strength the Bioventix share price has outperformed the FTSE All Share Index by +0.68% over the past year.
There is no consensus recommendation for this security.
The Bioventix dividend yield is 3.63% based on the trailing twelve month period.
Last year, Bioventix paid a total dividend of £1.58, and it currently has a trailing dividend yield of 3.63%. We do not have any data on when Bioventix is to next pay dividends.
We do not have data on when Bioventix is to next pay dividends. The historic dividend yield on Bioventix shares is currently 3.63%.
To buy shares in Bioventix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 4,350.00p, shares in Bioventix had a market capitalisation of £227.06m.
Here are the trading details for Bioventix:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: BVXP
Based on an overall assessment of its quality, value and momentum Bioventix is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bioventix is 5,900.00p. That is 35.63% above the last closing price of 4,350.00p.
Analysts covering Bioventix currently have a consensus Earnings Per Share (EPS) forecast of £1.66 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioventix. Over the past six months, its share price has underperformed the FTSE All Share Index by -4.74%.
As of the last closing price of 4,350.00p, shares in Bioventix were trading +2.74% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioventix PE ratio based on its reported earnings over the past 12 months is 24.3. The shares last closed at 4,350.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioventix's management team is headed by:
- Ian Nicholson - NEC
- Peter Harrison - CEO
- Bruce Hiscock - CFO
- Treena Turner - NED
- Nick McCooke - NID